FDA has granted accelerated approval to Xpovio for multiple myeloma
The FDA ( Food and Drug Administration ) has granted accelerated approval to Xpovio ( Selinexor ) in combination with Dexamethasone for adult patients with relapsed or refractory multiple myeloma ( RRMM ) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Efficacy was evaluated in 122 patients enrolled in Part 2 of STORM, a multicenter, single-arm, open-label study of patients with relapsed or refractory multiple myeloma who had previously received three or more anti-myeloma treatment regimens including an alkylating agent, glucocorticoids, Bortezomib, Carfilzomib, Lenalidomide, Pomalidomide, and an anti-CD38 monoclonal antibody.
In addition, the disease was refractory to glucocorticoids, a proteasome inhibitor, an immunomodulatory agent, an anti-CD38 monoclonal antibody, and to the last line of therapy.
These patients were treated with Selinexor ( 80 mg ) in combination with Dexamethasone ( 20 mg ) on days 1 and 3 of every week.
The approval was based on efficacy and safety in a prespecified subgroup analysis of 83 patients whose disease was refractory to Bortezomib, Carfilzomib, Lenalidomide, Pomalidomide, and Daratumumab.
The overall response rate was 25.3% ( 95% CI: 16.4, 36 ), with 1 stringent complete responses ( CR ), no complete response, 4 very good partial responses and 16 partial responses.
The median time to first response was 4 weeks ( range: 1 to 10 weeks ).
The median response duration was 3.8 months ( 95% CI: 2.3, not estimable ).
The efficacy evaluation was supported by additional information from an ongoing, randomized trial in patients with multiple myeloma.
Common adverse reactions reported in at least 20% of patients include thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.
The recommended Selinexor dose is 80 mg in combination with Dexamethasone taken orally on days 1 and 3 of each week. ( Xagena )
Source: FDA, 2019
Rinvoq, an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Rinvoq ( Upadacitinib ), a 15 mg, once-daily oral...
Inrebic for patients with intermediate-2 or high-risk primary or secondary myelofibrosis, approved by FDA
The FDA ( Food and Drug Administration ) has approved Inrebic ( Fedratinib ) for adults with intermediate-2 or high-risk...
Relapsed and refractory multiple myeloma: European Commission has approved Empliciti plus Pomalidomide and low-dose Dexamethasone
The European Commission ( EC ) has approved Empliciti ( Elotuzumab ) plus Pomalidomide and low-dose Dexamethasone ( EPd )...
Xospata as a monotherapy for patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation, approved in European Union
The European Commission ( EC ) has approved the oral once-daily therapy Xospata ( Gilteritinib ) as a monotherapy for...
Long-term efficacy and safety of first-line Ibrutinib treatment for patients with chronic lymphocytic leukemia / small lymphocytic lymphoma: 5 years of follow-up from RESONATE-2 trial
RESONATE-2 is a phase 3 study of first-line Ibrutinib ( Imbruvica ) versus Chlorambucil in chronic lymphocytic leukemia ( CLL...
FDA: Reblozyl for the treatment of anemia in adult patients with beta-thalassemia who require regular RBC transfusions
The FDA ( U.S. Food and Drug Administration ) has granted approval to Reblozyl ( Luspatercept–aamt; Luspatercept ) for the...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Polatuzumab vedotin-piiq ( Polivy; Polatuzumab vedotin ),...
DRIVE PK Study in patients with pyruvate kinase deficiency: data for Mitapivat from Core and Extension phases
New data from the core and extension phases of the DRIVE PK phase 2 study of Mitapivat ( AG-348 )...
Keytruda as first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma: two new regimens approved by European Commission
The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...